Sarepta Therapeutics | SRPT - Assets


Sarepta Therapeutics reported $3.18B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Acadia Pharmaceuticals USD 1.61B 41.04M Mar/2026
Agios Pharmaceuticals USD 1.18B 112.24M Mar/2026
Alnylam Pharmaceuticals USD 5.13B 163.22M Mar/2026
Amgen USD 92.5B 1.92B Mar/2026
BioCryst Pharmaceuticals USD 465.05M 49.11M Mar/2026
Biogen USD 29.48B 43.6M Mar/2026
BioMarin Pharmaceutical USD 8.59B 996.99M Mar/2026
Capricor Therapeutics USD 326.28M 29.66M Mar/2026
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Eli Lilly USD 116.58B 4.1B Mar/2026
Esperion Therapeutics USD 462.53M 3.36M Mar/2026
Gilead Sciences USD 56.28B 2.74B Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Insmed USD 2.08B 188.7M Mar/2026
Ionis Pharmaceuticals USD 3.45B 74M Mar/2026
Moderna USD 11.49B 850M Mar/2026
Nektar Therapeutics USD 280.41M 20.94M Dec/2025
Neurocrine Biosciences USD 4.91B 274.7M Mar/2026
Novavax USD 1.04B 133.35M Mar/2026
Pfizer USD 207.62B 542M Mar/2026
PTC Therapeutics USD 2.87B 29.66M Mar/2026
Regeneron Pharmaceuticals USD 40.87B 310.1M Mar/2026
Roche Holding CHF 100.7B 5.94B Dec/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Sanofi EUR 128.02B 1.22B Mar/2026
Sarepta Therapeutics USD 3.18B 170.77M Mar/2026
Tectonic Therapeutic USD 246.58M 14.46M Mar/2026
Ultragenyx Pharmaceutical USD 1.3B 236M Mar/2026
Vertex Pharmaceuticals USD 26.48B 841.4M Mar/2026